In previous studies, we have observed that antagonism of angiotensin or endothelin receptors prevented the development of nephroangio-and glomerulo-sclerosis during hypertension by inhibiting collagen I gene synthesis, through a mechanism independent of systemic haemodynamics. The present study investigated whether treatment with angiotensin or endothelin receptor antagonists, given at doses that did not reduce blood pressure, could produce regression of renal sclerotic lesions and improve renal function during hypertension. Hypertension and renal vascular fibrosis were induced in rats by chronic inhibition of NO synthesis using N G -nitro-L-arginine methyl ester (L-NAME). Systolic blood pressure gradually increased following L-NAME administration, reaching a plateau of 170 mmHg after four weeks of treatment. At the same time, urinary protein excretion and plasma creatinine concentration were increased ten-and three-fold compared with controls, respectively (p<0.001). This increase was accompanied by the appearance of sclerotic lesions within renal vessels and glomeruli, as evidenced by Masson's trichromic staining (sclerotic index 2.34±0.29 vs. 0.10±0.01 in L-NAME four weeks and control, respectively, p<0.001). Thereafter, the L-NAME treatment was combined with either losartan (an AT 1 -receptor antagonist), bosentan (an ET A/B antagonist), co-treatment with both agents, or vehicle for an additional period of four weeks. Blockade of AT 1 -and/or ET A/B -receptors significantly reduced urinary protein excretion and plasma creatinine levels (p<0.01) and substantially improved renal vascular histology (sclerotic index 1.78±0.13, 1.57±0.22 and 1.85±0.15 respectively, p<0.01, vs. L-NAME eight week) without altering the L-NAME-induced increase of systolic pressure. These data indicate that angiotensin II and endothelin-1 participate in the mechanism(s) of renal vascular fibrosis by increasing extracellular matrix formation. Treatment with their respective receptor antagonists leads to the regression of renal vascular fibrosis and to the improvement of renal function by a common antifibrogenic mechanism that is independent of systemic haemodynamics.
Introduction
Development of renal sclerotic lesions is one of the most common complications of hypertension. 1 This pathophysiological process is associated with changes in the structure of renal vasculature due to abnormal accumulation of extracellular matrix (collagens type I and III) in renal resistance vessels, glomeruli and interstitium. 2 The progression of fibrosis could be considered as an adaptive response of the vascular wall either to increased tension and/or to the activation of local profibrogenic systems. Recent animal and human studies support a central role for the renin-angiotensin system in the development of vascular and renal fibrosis. 3, 4 Although it is well-established that blockade of angiotensinconverting enzyme (ACE) reduces the progression of renal fibrosis, it remains unclear whether this protective effect is exclusively due to a decrease in renal vascular resistance or whether other, pressure-independent, mechanism(s) are operating. 5 Endothelial vasoactive agents such as nitric oxide (NO) and endothelin-1 could also be involved in this pathophysiological process. NO is an important inhibitor of vascular smooth muscle cell growth and extracellular matrix synthesis in vitro and in vivo, 6, 7 while chronic inhibition of NOsynthesis by N G -nitro-L-arginine methyl ester (L-NAME) is accompanied by renal vascular fibrosis. 8, 9 On the other hand, endothelin-1 is a potent mitogenic agent in cultured vascular smooth muscle cells and mesangial cells, [10] [11] [12] and endothelin-1 antagonism prevented the development of vascular hypertrophy and fibrosis in several forms of experimental hypertension such as the DOCAsalt, angiotensin II-(Ang II) or L-NAME-models. [13] [14] [15] In previous studies, we investigated the role of Ang II, NO and endothelin-1 in the mechanisms of renal vascular fibrosis, using a strain of transgenic mice that express the luciferase reporter gene under the control of the promoter of the α2 chain of collagen I gene (procolα2(I)). 16 Using this transgenic model, we concluded that Ang II and endothelin-1 played an important role in the abnormal expression of the collagen I gene during the development of hypertension induced by L-NAME, because the administration of AT 1 or ET A/B receptor antagonists in a preventive mode protected kidneys from the development of fibrosis. Ang II and endothelin-1 activated collagen I gene in renal vessels and glomeruli, independently of the increase in systolic pressure. Moreover, we found that the fibrogenic effect of Ang II was, at least partly, mediated by an endothelin-1 action on the collagen I gene. 16, 17 However, the experimental design of our previous studies did not allow conclusions about another important question, that is whether or not these antagonists can delay the progression of the sclerotic lesions in the renal vasculature, or even make them regress. This hypothesis of a possible curative effect of these drugs was examined in the present study. Our findings imply that Ang II and endothelin-1 are involved in the formation and maintenance of extracellular matrix within the renal vasculature in the NO-deficiency model of hypertension. Receptor antagonism of these peptides at nondepressor doses was accompanied by a regression of vascular and glomerular fibrosis and improvement in renal function.
Methods

Experimental protocol
Male Sprague-Dawley rats, weighing 250 g at the time of the experiments, were maintained on a normal salt diet. Animals had free access to chow and tap water. NO synthesis was inhibited by administrating the NO synthase inhibitor (L-NAME) (20 mg/kg/day). We have previously found that this dose produced a gradual elevation of blood pressure (BP), accompanied by the appearance of glomerular and renal vascular lesions after three to four weeks of treatment. 18 After four weeks of L-NAME treatment (when lesions appeared to reach more than 75% of glomeruli), rats were divided into four subgroups: the first continued to receive L-NAME; in the second, third and fourth groups, losartan (10 mg/kg/day), an AT 1 -receptor antagonist, bosentan (30 mg/kg/day), a dual endothelin receptor antagonist, or a combination of losartan and bosentan were co-administered with L-NAME, respectively, for an additional period of four weeks. Ten rats were utilised per experimental group. These doses did not affect the L-NAMEinduced increase in BP. The choice of doses was based on preliminary experiments and previously published data. 18 The vehicle-receiving controls were also divided in to four subgroups with pharmacological treatment similar to the L-NAME rats.
Measurement of blood pressure
Systolic blood pressure (SBP) was measured by the tail-cuff method as previously described. 18 Briefly, a piezoelectric sensor (Sensonor 840-01), connected to a carrier amplifier (Kent 2), was used to detect and convert heart pulses to electrical signals. The outputs of the pressure transducer were interfaced to a data acquisition system composed of a Power PC Macintosh 4400/200 computer and a MacLab/4s 16-bit analog-to-digital converter (ADInstruments) allowing sampling at 40,000 samples/s. Pressure recording was analysed using the Chart module of the MacLab software.
To avoid clinical variations in BP, all measurements were carried out between 0900 hours and 1100 hours.Animals were acclimatised for several days before measurements were made. Eight measurements from each rat were taken at 2-minute intervals, and a mean value was determined.
Renal histology
Kidneys from at least five rats from each group were immersed in Dubosq solution. After fixation, four to six cortical slices of each kidney were embedded in paraffin after conventional processing (alcohol dehydration), and 3 µm-thick sections were stained with Masson trichromic solution for staining of extracellular matrix proteins.
Morphologic evaluation
Sections of kidneys were examined on a blinded basis for the level of glomerular sclerosis and microvascular injury, using the 0-4+ injury scale, as previously described. 16 Injury scale 0 means no exaggerated extracellular matrix deposition in glomeruli, while 1+,2+,3+, and 4+ correspond to 1-25, 26-50, 51-75, and 76-100% of increased extracellular matrix deposition per glomeruli, respectively. The sclerotic index was considered to be equal to the sum: 1xA+2xB+3xC+4xD, where A, B, C and D represent the percentage of glomeruli belonging to classes 1-4, respectively. Sclerotic indices of individual sections were averaged to calculate a sclerotic index for each rat. At least 500 glomeruli were scored to estimate the sclerotic index of a rat.
Measurement of urinary protein excretion
The day before sacrifice, animals were transferred into metabolic cages and urine samples were collected for a 24-hour period. Urinary protein concentration was normalised to urinary creatinine concentration, and values were expressed as mg of protein per µmol of creatinine.
Measurement of plasma creatinine
Blood samples were drawn on the last day of the study and creatinine was measured by the automated Jaffe's method. Plasma creatinine concentrations were expressed as µmol/l.
Statistical methods
Statistical analyses were performed using ANOVA followed by Protected Least Significance Difference Fisher's test of the Statview software package. Results with p<0.05 were considered statistically significant.All values are means±SEM.
Results
Effect of L-NAME treatment on renal vascular structure and function
In agreement with our previous results, SBP rose after four weeks of L-NAME treatment (167±5 vs. 111±3 mmHg, p<0.01). At the same time, renal vascular and glomerular fibrosis was clearly established, as evidenced by Masson's staining ( Figure  1B ). Semiquantitative evaluation of extracellular matrix formation after four weeks of L-NAMEtreatment confirmed renal injury in L-NAMEtreated vs. control rats. Seventy one percent of glomeruli displayed extracellular matrix scores from 2+ to 4+ (sclerotic index 2.34±0.29 vs. 0.10±0.01 in L-NAME four week and control, respectively, p<0.001, Figure 2 ). These structural changes were associated with deterioration of Effects of angiotensin II or endothelin-1 receptor antagonism on the extracellular matrix formation, renal function and survival rate At the doses used, losartan or bosentan did not alter SBP (177±5 vs. 175±4 or 171±5 mmHg, in rats treated with L-NAME for eight weeks and L-NAME four weeks followed by four weeks of L-NAME+losartan or bosentan, respectively). Losartan or bosentan administration to control animals did not modify BP (data not shown). Contrary to their effect on BP, both treatments markedly protected kidneys from L-NAMEinduced fibrosis, as evidenced by the reduced levels of extracellular matrix staining in L-NAME+losartan ( Figure 1D ) or L-NAME+bosen-tan (data not shown) compared with the L-NAME eight week ( Figure 1C) group. Semiquantitative analysis of fibrosis indicated that 45% of glomeruli exhibited a severe degree of glomerular injury (4+) in the L-NAME group (sclerotic index 3.06±0.34) (Figure 2 ), whereas there were less than 12% of glomeruli in class 4+ in the L-NAME+losartan or the L-NAME+bosentan groups (sclerotic index 1.78±0.13 or 1.57±0.22, respectively, p<0.01, vs. L-NAME eight weeks, Figure 2 ). It is noteworthy that both antagonists blunted the degree of glomerulosclerosis even compared with the L-NAME four week group (p<0.05, Figure 2 ). This improvement of renal vascular histology during co-treatment with losartan or bosentan was accompanied by a marked improvement in renal function, as proteinuria and creatininaemia were significantly decreased (Figures 3 and 4) . Survival rate was also markedly increased by these drugs (80% vs. 25% in the L-NAME eight weeks, p<0.001).
Effects of combination of AT 1 and ET A/B receptor antagonism against the progression of renal vascular fibrosis
Since our previous data indicated that the stimulatory effect of Ang II on collagen I gene activation was mediated by endothelin-1, we further pursued this hypothesis by examining what degree of protection against renal fibrosis would be provided by a combination of AT 1 -and endothelin receptor antagonism. As shown in Figure 2 , extracellular matrix formation and the sclerotic index were significantly reduced in the L-NAME+losartan+bosen-tan group compared with L-NAME four or eight weeks; however, renal histology was not improved compared with L-NAME+losartan or L-NAME+ bosentan groups (Figures 1 and 2) . Similar observations were made with the parameters of renal function. Urinary protein excretion and plasma creatinine concentrations were reduced in the L-NAME+ losartan+bosentan group compared with L-NAME four or eight weeks, but were similar to the values observed when these two antagonists were administered separately (Figures 3 and 4) . Similarly, the survival rate in this group was improved compared with L-NAME eight weeks (85% vs. 25%, respectively, p<0.001), but it did not significantly differ from that of the L-NAME+losartan or L-NAME+bosentan groups (80%).
Discussion
In the present study, we investigated mechanisms of regression of renal vascular fibrosis. An important novel finding is that Ang II or endothelin receptor antagonists, reduced the severity of renal lesions and improved renal function at doses that 
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did not alter SBP. Furthermore, a combination of the two drugs did not produce additional protective effects.These data suggest that antagonism of these peptides could reverse renal fibrosis associated with NO deficiency by a common renal mechanism, independent of systemic haemodynamics. Several studies have demonstrated the involvement of the renin-angiotensin and endothelin-1 system in the development of renal, vascular and cardiac fibrosis. [19] [20] [21] [22] [23] [24] Some of these studies are in favour of the independence between the fibrogenic and the haemodynamic actions of Ang II and endothelin-1. Thus, expression of collagen type I gene was increased in the right ventricle, a compartment exposed to a relatively low systolic pressure, 19 while ACE inhibitors (ACE-I), but not hydralazine, prevented vascular and myocardial remodelling in L-NAME-treated rats, despite the similarity of SBP levels between these two groups. 20 Selective blockade of the ET A receptor prevented proteinuria and glomerular ischaemia and blunted the degree of vascular and tubulointerstitial injury during inhibition of NO synthesis without normalising BP. 25 Our previous studies provided additional clues to the mechanisms by which Ang II and endothelin-1 participate in the development of renal vascular fibrosis. We have found that, during chronic inhibition of NO synthesis, there is a local activation of the collagen I promoter in renal microvessels and glomeruli. Losartan or bosentan, given in a preventive way, abolished the exaggerated gene expression and peptide synthesis of collagen I, and markedly protected the renal vasculature from the development of fibrosis. 16, 17 These protective effects of Ang II and endothelin-1 antagonism occurred despite the persistent increase of systolic pressure in L-NAME-treated animals.
The above-cited studies focused on the mechanisms leading to the development of renal vascular fibrosis, in the presence or absence of preventative pharmacological treatments. Little is known regarding the efficiency of Ang II-or endothelinreceptor antagonists as curative drugs in promoting the regression of renal fibrosis.This issue was addressed by the present study. We found that blockade of the renin-angiotensin or endothelin-1 systems, after the formation of renal sclerotic lesions, decreased the abnormal presence of extracellular matrix within the renal vasculature and improved two parameters related to glomerular function, proteinuria and creatininaemia. Animals receiving losartan or bosentan displayed less severe histological lesions and exhibited decreased proteinuria and creatininaemia, even compared with those at the beginning of four weeks L-NAME treatment. This improvement in renal histology and function was accompanied by a marked protection against mortality, despite the fact that animals continued to be hypertensive. Of course, mortality was not completely eliminated by losartan or bosentan. A possible explanation is that some animals were terminally ill when treatment with these drugs was initiated, and could not be rescued. This hypothesis is supported by the fact that the mortality rate was already 20% in the animals after just four weeks of L-NAME. Another possible explanation is that renal failure is not the sole cause of mortality in the L-NAME eight week group; losartan or bosentan improved renal histol-
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Figure 2
Index of sclerosis in glomeruli from controls and rats treated for four or eight weeks with L-NAME, or four weeks with L-NAME followed by co-administration of L-NAME with either losartan, bosentan or association of these two for four additional weeks. * p<0.05 vs. control; # p<0.05 vs. L-NAME.
Figure 3
Protein concentration in urine from controls and rats treated for four or eight weeks with L-NAME, or four weeks with L-NAME followed by co-administration of L-NAME with either losartan, bosentan or association of these two for four additional weeks. * p<0.05 vs. control; # p<0.05 vs. L-NAME.
Figure 4
Creatinine concentration in plasma from controls and rats treated for four or eight weeks with L-NAME, or four weeks with L-NAME followed by coadministration of L-NAME with either losartan, bosentan or association of these two for four additional weeks. * p<0.05 vs. control; # p<0.05 vs. L-NAME. 
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PAPER ogy and function but, since they were administered at non-depressor doses, they had no effect on complications directly related to high BP, such as stroke. Whatever the case, our data imply that, at least in this model of hypertension, the local action of paracrine systems (such as Ang II or endothelin-1) in target organs (such as the kidney) is more susceptible to induce end-organ damage than the high BP per se. Conversely, blockade of the action of these systems can regress renal vascular fibrosis and improve renal function, independent of SBP.
The notion that the abnormal formation of extracellular matrix around vessels is a dynamic process, that can be reversed, and that an efficient antihypertensive treatment should also address the issue of pathological structural remodelling, has recently emerged from animal and human studies, performed mainly in cardiac and aortic tissues. [26] [27] [28] [29] [30] Contrary to the heart, few data are available on regression of fibrosis in the kidney, another target organ of hypertension. Treatment with a calcium channel blocker and/or an ACE-I improved renal heamodynamics and prevented nephrosclerosis in SHR treated with L-NAME. 31 In the L-NAME model of hypertension in rats, blockers of Ang II activity preserved kidney function and morphology in addition to normalising systolic pressure. 22, 32 In these studies, however, antihypertensive treatments were introduced before the development of sclerotic lesions within the kidney. Thus, these experimental approaches demonstrated the efficiency of Ang II antagonists against the progression of renal lesions rather than the regression of pre-established sclerotic lesions. Our data provide new insights into the paracrine action of the renin-angiotensin system on the development of renal vascular sclerosis and its reversibility. Importantly, in support of the notion that renal fibrosis can also regress in human disease, reversal of the lesions of diabetic nephropathy was recently observed in renal biopsies of pancreas graft recipients, ten years after normalisation of glycaemia. 33 Combination of Ang II-with endothelin-1-receptor antagonists gave contrasting results regarding their efficiency to protect or to improve renal function and/or structure. For instance, glomerulosclerosis and tubulointerstitial damage were reduced more by combined therapy than by each treatment separately in a model of membranous nephropathy. 34 In contrast, no additional beneficial effect was observed when Ang II blockade was combined with an ET A or ET A/B antagonists in the 5/6 nephrectomy model of progressive renal injury. 35 In our study, the combination of losartan and bosentan did not produce additional improvement of renal morphology or function. This observation suggests that the fibrogenic actions of Ang II and endothelin-1 share common mechanism(s) and supports our previous data showing that the Ang II-induced activation of collagen I gene on renal vessels was cancelled not only by an AT 1 -receptor antagonist (as was expected), but also by an ET A/B antagonist. 17 However, these common mechanisms account for a part of the renal vascular fibrosis observed after eight weeks of L-NAME, since the sclerotic index was reduced by about 33% with the curative treatments ( Figure 2 ).
In conclusion, we investigated mechanisms of regression of renal vascular and glomerular fibrosis during hypertension induced by prolonged NO deficiency. Our data indicate that treatment with Ang II-or endothelin-1-receptor antagonists leads to the regression of renal lesions and improvement in the renal function, independently of systemic haemodynamics, at least in this hypertensive model. This observation may have important implications in the treatment of nephroangio-and glomerulo-sclerosis in human essential hypertension.
